Long acting GLP-1 receptor agonist (injectable)
Efpeglenatide 2 mg subcutaneous once weekly
EFPE_SC_2MG_QW
Related
- All doses pooled: Efpe sc
- Efpe sc 1mg qw
- Efpeglenatide 4 mg subcutaneous once weekly
- Efpe sc 8mg qm
- Efpe sc 12mg qm
- Efpeglenatide 16 mg injection monthly
- Efpeglenatide 8 mg injection every 4 weeks
- Efpeglenatide 12 mg injection every 4 weeks
- Efpeglenatide 16 mg injection every 4 weeks
- Efpeglenatide 6 mg subcutaneous once weekly
- Efpeglenatide 6 mg injection every 2 weeks
- Efpeglenatide 8 mg injection every 2 weeks
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.21 (-2.07 to 1.60) | 0.19 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -0.73 (-1.81 to 0.47) | 0.36 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD 0.44 (-3.91 to 4.94) | 0.37 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD 0.18 (-4.46 to 4.89) | 0.53 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 3.58 (0.67 to 13.06) | 0.25 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 36 to 64 (target week 52) | Placebo | OR 3.41 (0.76 to 10.09) | 0.41 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.41 (0.00 to 19.75) | 0.50 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.32 (0.00 to 8.90) | 0.75 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.25 (0.52 to 3.17) | 0.38 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 1.70 (0.55 to 5.48) | 0.48 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 2.14 (0.55 to 9.55) | 0.55 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 2.91 (0.45 to 24.95) | 0.46 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.98 (0.37 to 2.60) | 0.69 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 1.47 (0.51 to 4.43) | 0.53 |
| Type 2 diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 1.53 (0.32 to 7.36) | 0.54 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 2.45 (0.21 to 26.90) | 0.26 |
| Type 2 diabetes (adults) | Acute kidney injury | longest follow-up | Placebo | HR 0.41 (0.01 to 17.05) | 0.58 |